News
StockStory.org on MSN9h
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services StocksAs the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...
10x Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in the United States District Court for the District of ...
Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...
Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with the ...
Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...
PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results